Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 3/20 | 0.61 |
| ▸ | GABBR2 | O75899 | 3/20 | 0.58 |
| ▸ | GABBR1 | Q9UBS5 | 3/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | DRD3 | P35462 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2556175 | 1.00 | FFAR1 (0.61) | FFAR1GABBR2GABBR1CYP2C9KMT2A | |
| SCHEMBL2554154 | 1.00 | FFAR1 (0.61) | FFAR1GABBR2GABBR1CYP2C9KMT2A | |
| SCHEMBL11332403 | 0.88 | FFAR1 (0.62) | FFAR1GABBR2GABBR1CYP2C9KMT2A | |
| SCHEMBL1225215 | 0.82 | GABBR2 (0.47) | FFAR1GABBR2GABBR1CYP2C9KMT2A | |
| SCHEMBL25152959 | 0.82 | ACHE (0.67) | FFAR1KMT2ACYP2C19TSHRPOLB | |
| SCHEMBL12883165 | 0.82 | ACHE (0.67) | FFAR1KMT2ACYP2C19TSHRPOLB | |
| SCHEMBL7559049 | 0.82 | ACHE (0.67) | FFAR1KMT2ACYP2C19TSHRPOLB | |
| SCHEMBL13140496 | 0.82 | FFAR1 (0.61) | FFAR1CYP2C9LMNACYP2D6CYP2C19 | |
| SCHEMBL31522488 | 0.82 | FFAR1 (0.61) | FFAR1CYP2C9LMNACYP2D6CYP2C19 | |
| SCHEMBL1162528 | 0.82 | FFAR1 (0.61) | FFAR1CYP2C9LMNACYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12502367-B2 | Oral baclofen solutions | Metacel Pharmaceuticals, LLC (US) | 2025-12-23 | — | — | US | claimed |
| US-20220233483-A1 | ORAL BACLOFEN SOLUTIONS | ROSEMONT PHARMACEUTICALS LLC | 2022-07-28 | — | — | US | claimed |
| EP-2922812-B1 | PROCESS FOR PREPARING A SALT OF A SULFURIZED ALKYL-SUBSTITUTED HYDROXYAROMATIC COMPOSITION | CHEVRON ORONITE CO (US) | 2021-08-11 | — | — | EP | claimed |
| EP-2922812-A1 | PROCESS FOR PREPARING A SALT OF A SULFURIZED ALKYL-SUBSTITUTED HYDROXYAROMATIC COMPOSITION | Chevron Oronite Company LLC (US) | 2015-09-30 | — | — | EP | claimed |
| US-8772209-B2 | Process for preparing a salt of a sulfurized alkyl-substituted hydroxyaromatic composition | CHEVRON ORONITE COMPANY LLS (US) | 2014-07-08 | — | — | US | claimed |
| WO-2014081538-A1 | PROCESS FOR PREPARING A SALT OF A SULFURIZED ALKYL-SUBSTITUTED HYDROXYAROMATIC COMPOSITION | CHEVRON ORONITE COMPANY LLC (US) | 2014-05-30 | — | — | WO | claimed |
| US-20140142347-A1 | PROCESS FOR PREPARING A SALT OF A SULFURIZED ALKYL-SUBSTITUTED HYDROXYAROMATIC COMPOSITION | CHEVRON ORONITE COMPANY LLC (US) | 2014-05-22 | — | — | US | claimed |
| CN-102341099-A | Sustained release oral dosage forms of an R-baclofen prodrug | XENOPORT INC | 2012-02-01 | — | — | CN | claimed |
| EP-2010508-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | AstraZeneca AB (SE) | 2009-01-07 | — | — | EP | claimed |
| WO-2007120096-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | claimed |
| EP-1786872-A1 | POWDER COATING COMPOSITIONS | PPG Industries Ohio, Inc. (US) | 2007-05-23 | — | — | EP | claimed |
| US-7132477-B2 | Powder coating compositions | PPG INDUSTRIES OHIO, INC. (US) | 2006-11-07 | — | — | US | claimed |
| WO-2006026492-A1 | POWDER COATING COMPOSITIONS | PPG INDUSTRIES OHIO, INC. (US) | 2006-03-09 | — | — | WO | claimed |
| US-20050025987-A1 | Powder coating compositions | PPG INDUSTRIES OHIO INC. | 2005-02-03 | — | — | US | claimed |
| US-12502367-B2 | Oral baclofen solutions | Metacel Pharmaceuticals, LLC (US) | 2025-12-23 | — | — | US | disclosed |
| US-12502367-B2 | Oral baclofen solutions | Metacel Pharmaceuticals, LLC (US) | 2025-12-23 | — | — | US | disclosed |
| EP-2922934-B1 | SOLVENT EXTRACTION FOR PREPARING A SALT OF A SULFURIZED ALKYL-SUBSTITUTED HYDROXYAROMATIC COMPOSITION | CHEVRON ORONITE CO (US) | 2022-12-14 | — | — | EP | disclosed |
| EP-0968206-A1 | N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS | BERLEX LABORATORIES, INC. (US) | 2000-01-05 | — | — | EP | disclosed |
| WO-1998037079-A1 | N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS | BERLEX LABORATORIES, INC. (US) | 1998-08-27 | — | — | WO | disclosed |
| US-4273873-A | BONDING SYNTHETIC FIBRINOLYTIC COMPOUND OR ENZYME | UNITIKA LTD. (JP) | 1981-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142347-A1 | PROCESS FOR PREPARING A SALT OF A SULFURIZED ALKYL-SUBSTITUTED HYDROXYAROMATIC COMPOSITION | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HTT, SEM1 | FFAR1 1580/4885GABBR2 2878/4885GABBR1 2884/4885 |
| US-12502367-B2 | Oral baclofen solutions | GABBR1, CA2, GABBR2 | FFAR1 609/4885GABBR2 3/4885GABBR1 1/4885 |
| US-20220233483-A1 | ORAL BACLOFEN SOLUTIONS | GABBR1, CA2, GABBR2 | FFAR1 609/4885GABBR2 3/4885GABBR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.